Argenx reported that Vyvgart sales have meaningfully exceeded prior expectations. The company highlighted progress in its clinical pipeline, with Phase 3 readouts upcoming for Vyvgart in new ...

IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from ...

If you or a loved one are living with hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), you are likely ...

As of Friday, February 06, Roivant Sciences Ltd.’s ROIV share price has surged by 17.48%, which has investors questioning if this is right time to sell.

Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”.

NTLA stock faces binary risk: success could unlock multi-billion dollar markets, while setbacks may erase hundreds of ...

Most generalized MG patients have ocular symptoms at presentation, which progress and cause generalized MG involving the ...

Even in remission, chronic inflammatory demyelinating polyneuropathy (CIDP) fatigue can be draining. Learn how to use the ...

While there is no cure for ALS, there have been about 65 rare cases where patients regain all, or nearly all, of their lost ...

Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said ...

Medications targeting the neonatal fragment crystallizable receptor have gained attention due to multiple recent FDA ...

By Kamal Choudhury Jan 27 (Reuters) - Intellia Therapeutics said on Tuesday that the U.S. drug regulator has lifted a ...